Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Express Scripts
Fish and Richardson
Citi
Moodys
Johnson and Johnson
Queensland Health
Teva
Fuji

Generated: June 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,722,898

« Back to Dashboard

Summary for Patent: 7,722,898
Title:Modified-release preparations containing oxcarbazepine and derivatives thereof
Abstract: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility-and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
Inventor(s): Bhatt; Padmanabh P. (Rockville, MD), Kidane; Argaw (Montgomery Village, MD), Edwards; Kevin (Lovettsville, VA)
Assignee: Supernus Pharmaceuticals, Inc. (Rockville, MD)
Application Number:11/734,874
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,722,898
Patent Claim Types:
see list of patent claims
Use; Formulation; Compound; Dosage form; Composition;

Drugs Protected by US Patent 7,722,898

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-001 Oct 19, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-002 Oct 19, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-003 Oct 19, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,722,898

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,617,600 Modified release preparations containing oxcarbazepine and derivatives thereof ➤ Sign Up
9,119,791 Modified release preparations containing oxcarbazepine and derivatives thereof ➤ Sign Up
9,119,792 Modified release preparations containing oxcarbazepine and derivatives thereof ➤ Sign Up
7,910,131 Method of treating seizures using modified release formulations of oxcarbazepine ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Fish and Richardson
Dow
US Department of Justice
Cantor Fitzgerald
Express Scripts
Cerilliant
Colorcon
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.